MetaCap

InflaRx N.V. (IFRX) vs Oramed Pharmaceuticals (ORMP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Oramed Pharmaceuticals (ORMP) has outperformed InflaRx N.V. (IFRX) over the past year, gaining 38.4% versus a loss of 11.9%. Over five years, IFRX leads with a -79.5% price change compared with -82.3% for ORMP. Oramed Pharmaceuticals is the larger company by market cap ($155.2 million vs $153.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IFRX-11.86%ORMP+38.37%
+140%+51%-38%
Nov 21, 20251 yearNov 20, 2026
IFRX-78.15%ORMP-86.53%
+21%-39%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IFRX versus ORMP key metrics
MetricIFRXORMP
Share price$1.04$3.57
Market cap$153.26M$155.24M
1-day change-4.59%-3.25%
YTD return+2.97%+25.26%
1-year return-11.86%+38.37%
5-year return-79.53%-82.34%
P/E ratio (TTM)—1.05
EPS (TTM)$-0.37$3.41
Dividend yield0.00%7.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.00M
Net income (latest FY)—$64.05M
Gross margin—0.65%
Operating margin—-754.40%
Net margin—3202.50%
52-week high$2.95$5.47
52-week low$0.798$2.52
Distance from 52-week high-64.73%-34.73%
Analyst consensusnonenone
Avg. price target upside+696.15%+96.08%
Average volume868.66K173.38K
Shares outstanding147.37M43.49M
Employees65—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ORMP has outperformed IFRX by 50.2 percentage points over the past year.
  • Oramed Pharmaceuticals offers a meaningfully higher dividend yield (7.00% vs 0.00%).

About InflaRx N.V.

IFRX stock →

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

About Oramed Pharmaceuticals

ORMP stock →

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

Health Care · Biotechnology: Pharmaceutical Preparations

IFRX vs ORMP FAQ

Which is bigger, InflaRx N.V. or Oramed Pharmaceuticals?

Oramed Pharmaceuticals (ORMP) is larger, with a market capitalization of $155.24M compared with $153.26M for InflaRx N.V. (IFRX).

Which stock has performed better over the past year, IFRX or ORMP?

ORMP returned +38.37% over the past 12 months, compared with -11.86% for IFRX (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, InflaRx N.V. or Oramed Pharmaceuticals?

Oramed Pharmaceuticals pays a dividend yielding 7.00%, while InflaRx N.V. does not currently pay a regular dividend.

Are InflaRx N.V. and Oramed Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons